Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Return on Capital Employed of 51.52% for Q1 2026, down 549.0% year-over-year from 11.47% in Q1 2025, and up 5.9% quarter-over-quarter from 54.75% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Return on Capital Employed for 13 consecutive years, with 51.52% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 549.0% year-over-year to 51.52%; the TTM figure through Mar 2026 stood at 51.52% (down 549.0% YoY), while the FY2025 annual figure was 47.2%, down 71.0% from the prior year.
- Return on Capital Employed rose to 51.52% in Q1 2026 per RARE's latest filing, from 54.75% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 32.02% in Q1 2022 and bottomed at 60.99% in Q2 2023.
- Historically, Return on Capital Employed has averaged 49.52% across 5 years, with a median of 49.73% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 2145 bps — and 2024, when it surged 1667 bps.
- Ultragenyx Pharmaceutical's Return on Capital Employed stood at 49.13% in 2022, then slipped by 7 bps to 52.48% in 2023, then increased by 13 bps to 45.55% in 2024, then declined by 20 bps to 54.75% in 2025, then climbed by 6 bps to 51.52% in 2026.
- Business Quant data shows RARE's Return on Capital Employed at 51.52% in Q1 2026, 54.75% in Q4 2025, and 59.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -56.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.85% |
| Mar 31, 2026 | -51.52% |
| Dec 31, 2025 | -54.75% |
| Sep 30, 2025 | -59.90% |
| Jun 30, 2025 | -49.73% |
| Mar 31, 2025 | -46.03% |
| Dec 31, 2024 | -45.55% |
| Sep 30, 2024 | -41.41% |
| Jun 30, 2024 | -46.11% |
| Mar 31, 2024 | -50.30% |
| Dec 31, 2023 | -52.48% |
| Sep 30, 2023 | -58.07% |
| Jun 30, 2023 | -60.99% |
| Mar 31, 2023 | -53.47% |
| Dec 31, 2022 | -49.13% |
| Sep 30, 2022 | -48.77% |
| Jun 30, 2022 | -41.59% |
| Mar 31, 2022 | -32.02% |
| Dec 31, 2021 | -28.87% |
| Sep 30, 2021 | -27.54% |